Trial · NCT03165721
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/Wild-Type GIST | Complete Response | 0 | Participants | |
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | Complete Response | 0 | Participants | |
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca | Complete Response | 0 | Participants | |
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/Wild-Type GIST | Partial Response | 0 | Participants | |
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | Partial Response | 0 | Participants | |
| Number of Participants With an Overall Response (Complete Response or Partial Response) of SGI-11 Using the Response Evaluation Criteria in Solid Tumors (RECIST) | Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca | Partial Response | 0 | Participants | |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/Wild-Type GIST | Baseline | 6.4 | Standard Deviation 1.4 | Scores on a scale |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | Baseline | 7 | Scores on a scale | |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca | Baseline | 2 | Scores on a scale | |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/Wild-Type GIST | End of cycle 4 | 4.5 | Standard Deviation 1.5 | Scores on a scale |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | End of cycle 4 | 2 | Scores on a scale | |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/Wild-Type GIST | Post therapy follow up, approximately 30 days after the final dose of study drug | 4.1 | Standard Deviation 2.4 | Scores on a scale |
| Change in Distress From Baseline | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | Post therapy follow up, approximately 30 days after the final dose of study drug | 3 | Scores on a scale | |
| Progression Free Survival Probability at 6 Months | Patients ≥ 12 Years of Age w/Wild-Type GIST | 85.7 | 95% Confidence Interval 33.4 to 97.9 | Percent probability | |
| Progression Free Survival Probability at 6 Months | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | 0 | Percent probability | ||
| Progression Free Survival Probability at 6 Months | Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca | 0 | Percent probability | ||
| Progression Free Survival (PFS) Probability at 12 Months | Patients ≥ 12 Years of Age w/Wild-Type GIST | 53.6 | 95% Confidence Interval 13.2 to 82.5 | Percent probability | |
| Progression Free Survival (PFS) Probability at 12 Months | Patients ≥ 12 Years of Age w/PHEO/PGL With SDH-deficient PHE | 0 | Percent probability | ||
| Progression Free Survival (PFS) Probability at 12 Months | Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca | 0 | Percent probability | ||
| Quality of Life (QOL) Relative to Any Degree of Response (Patient-Reported Outcomes Measurement Information System (PROMIS) Global Physical Health) | Patients ≥ 12 Years of Age w/Wild-Type GIST | Baseline | 45.9 | 95% Confidence Interval 40.5 to 51.3 | t-score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03165721/results